MSI、PD—L1及IL—6在结直肠腺癌中的表达及意义(4)
[5] Korehisa S，Oki E，Iimori M，et al.Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability[J].Int J Cancer，2018，142(4)：822-832.
[6] Inoue Y，Miki C，Watanabe H，et al.Genomic instability and tissue expression of angiogenic growth factors in sporadic colorectal cancer[J].Surgery，2006，139(3)：305-311.
[7] Hancock J F.Ras proteins：different signals from different locations[J].Nat Rev Mol Cell Biol，2003，4：373-384.
[8] Lorenc Z，Waniczek D，Lorenc-Podgórska K，et al.Profile of Expression of Genes Encoding Matrix Metallopeptidase 9(MMP9)，Matrix Metallopeptidase 28(MMP28) and TIMP Metallopeptidase Inhibitor 1(TIMP1) in Colorectal Cancer：Assessment of the Role in Diagnosis and Prognostication[J].Med Sci Monit，2017，23：1305-1311.
[9] Fletcher R，Wang Y J，Schoen R E，et al.Colorectal cancer prevention：Immune modulation taking the stage[J].Biochim Biophys Acta，2018，1869(2)：138-148.
[10] Pardoll D M.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer，2012，12(4)：252-264.
[11] O’Neil B H，Wallmark J M，Lorente D，et al.Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma[J].PLoS One，2017，12(12)：e0189848.
[12] Topalian S L，Sznol M，Mcdermott D F，et al.Survival， durable tumor remission， and long-term safety in patients with advanced melanoma receiving nivolumab[J].Journal of Clinical Oncology，2014，32(10)：1020-1030.
[13] Ribas A，Shin D S，Zaretsky J，et al.PD-1 Blockade Expands Intratumoral Memory T Cells[J].Cancer Immunology Research，2016，4(3)：194-203.
[14] Ohno Y，Toyoshima Y，Yurino H，et al.Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy[J].Cancer Sci，2017，108(10)：1959-1966.
[15] Xiao Y，Freeman G J.The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy[J].Cancer Discov，2015，5(1)：16-18.
(收稿日期：2018-04-03) (本文編辑：张爽), 百拇医药(王超 郑绘霞)
[6] Inoue Y，Miki C，Watanabe H，et al.Genomic instability and tissue expression of angiogenic growth factors in sporadic colorectal cancer[J].Surgery，2006，139(3)：305-311.
[7] Hancock J F.Ras proteins：different signals from different locations[J].Nat Rev Mol Cell Biol，2003，4：373-384.
[8] Lorenc Z，Waniczek D，Lorenc-Podgórska K，et al.Profile of Expression of Genes Encoding Matrix Metallopeptidase 9(MMP9)，Matrix Metallopeptidase 28(MMP28) and TIMP Metallopeptidase Inhibitor 1(TIMP1) in Colorectal Cancer：Assessment of the Role in Diagnosis and Prognostication[J].Med Sci Monit，2017，23：1305-1311.
[9] Fletcher R，Wang Y J，Schoen R E，et al.Colorectal cancer prevention：Immune modulation taking the stage[J].Biochim Biophys Acta，2018，1869(2)：138-148.
[10] Pardoll D M.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer，2012，12(4)：252-264.
[11] O’Neil B H，Wallmark J M，Lorente D，et al.Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma[J].PLoS One，2017，12(12)：e0189848.
[12] Topalian S L，Sznol M，Mcdermott D F，et al.Survival， durable tumor remission， and long-term safety in patients with advanced melanoma receiving nivolumab[J].Journal of Clinical Oncology，2014，32(10)：1020-1030.
[13] Ribas A，Shin D S，Zaretsky J，et al.PD-1 Blockade Expands Intratumoral Memory T Cells[J].Cancer Immunology Research，2016，4(3)：194-203.
[14] Ohno Y，Toyoshima Y，Yurino H，et al.Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy[J].Cancer Sci，2017，108(10)：1959-1966.
[15] Xiao Y，Freeman G J.The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy[J].Cancer Discov，2015，5(1)：16-18.
(收稿日期：2018-04-03) (本文編辑：张爽), 百拇医药(王超 郑绘霞)